Melanoma Clinical Trials

Showing 121-140 of 1,292 trials

Personalized Circulating DNA Follow-up in Melanoma (PERCIMEL)

NCT04866680

PERCIMEL is an open multicentric study. The purpose of this study is to assess the interest of molecular analysis on circulating tumor DNA in the follow-up of the disease.

Melanoma

Institut de Cancérologie de Lorraine136 participantsStarted Jan 2023

Besançon, France • Dijon, France • Dijon, France +5 more locations

Active Not RecruitingPhase 1

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

NCT04044859

This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen. Tumor indications include endometrial, esophageal, esophagogastric junction (EGJ), gastric, head and neck, melanoma, non-small cell lung (NSCLC), ovarian or urothelial cancer.

Endometrial CancerEsophageal CancerEsophagogastric Junction (EGJ)+6 more

USWM CT, LLC120 participantsStarted Aug 2019

Orlando, Florida, United States • Boston, Massachusetts, United States • St Louis, Missouri, United States +14 more locations

Personalized Circulating DNA Follow-up in Melanoma (PERCIMEL)

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

Related Searches

Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED

A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma

Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs

Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

A Study of MGC026 in Participants With Advanced Solid Tumors

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study

Treating Patients With Melanoma and ALK Alterations With Ensartinib

Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma

Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.

Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients